Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNTech SE

www.biontech.de

Latest From BioNTech SE

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.

BioPharmaceutical Research and Development Strategies

BioNTech Bags Bargain With Neon Buy

Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.

M & A ImmunoOncology

European Biotechs Enter the IPO Big League

2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.

Europe Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • BioNTech SE
  • Senior Management
  • Ugur Sahin, MD, CEO
    Sierk Poetting, PhD, CFO & COO
    Sean Marett, CBO & Chief Commercial Officer
    Özlem Türeci , MD, CMO
    Ryan Richardson, Chief Strategy Officer
  • Contact Info
  • BioNTech SE
    Phone: 6131 9084 0
    An der Goldgrube 12
    Mainz, D-55131
    Germany
UsernamePublicRestriction

Register